Breast Cancer

TNBC treatment: platinum-based therapy and PARP inhibition

BROCADE3: veliparib with carboplatin/paclitaxel in HER2-/BRCA+ advanced breast cancer

HER-2 conversion: a phenomenon in trastuzumab resistance

Real-world clinical outcomes in metastatic breast cancer patients treated with palbociclib

IMpower110: atezolizumab vs chemo in PD-L1–selected NSCLC

KEYNOTE 522: pembrolizumab as neoadjuvant treatment for early TNBC

Targeted therapy in TNBC

Adding alpelisib for HR+/HER2- advanced breast cancer in SOLAR-1: adverse event impacts

BYLieve additional cohort: update on the trial of alpelisib in advanced breast cancer from ESMO

MONALEESA-3 OS results: fulvestrant/ribociclib in postmenopausal HR+/HER2- advanced breast cancer

Phase 3 KEYNOTE-522 results: pembro/chemo neoadjuvant, pembro adjuvant in early TNBC

MONARCH 2: abemaciclib added to fulvestrant shows OS benefit in HR+/HER2- advanced breast cancer

IMpassion130: Implications

IMpassion130: immunotherapy for TNBC

TNBC: work to be done

Breast and prostate cancer: maintaining skeletal integrity